Meningitis

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Retrieved on: 
Tuesday, February 21, 2023
Vaccine, Fungal infection, Life, Lead, Genetically modified bacteria, Safety, Infant, Tolerability, Food, Meningitis, Investigational New Drug, Disease, FDA, SAN, PCV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IPD, Immunization, IND, Ageing

SAN CARLOS, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s infant Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD). Vaxcyte plans to initiate the infant Phase 2 study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data following the primary three-dose immunization series expected by 2025. The study design will include a primary immunization series consisting of three doses followed by a subsequent booster dose.

Key Points: 
  • Vaxcyte plans to initiate the infant Phase 2 study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data following the primary three-dose immunization series expected by 2025.
  • The study design will include a primary immunization series consisting of three doses followed by a subsequent booster dose.
  • The burden of disease in the pediatric population underscores the need for a broader-spectrum vaccine.
  • Importantly, the nine incremental serotypes in VAX-24 cover an additional 20-25 percent of strains causing IPD over the current 15-valent standard-of-care PCV in infants.

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Retrieved on: 
Monday, February 13, 2023
Health, Clinical Trials, Biomarker, Regenerative medicine, Meningitis, Therapy, MRI, Safety, Sensorineural hearing loss, VEP, Hearing loss, Patient, CSO, Clinical trial, Frequency, Interim, Magnetic resonance imaging, Speech perception, Myelin, MS, Remyelination, SNHL, Pharmaceutical industry

The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss, failed to achieve its primary efficacy endpoint of an improvement in speech perception.

Key Points: 
  • The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss, failed to achieve its primary efficacy endpoint of an improvement in speech perception.
  • Prior FX-322 studies had been designed to best understand patient etiologies and severities where a hearing signal could be observed.
  • The safety profile associated with FX-322 was favorable and no study participants experienced a serious adverse event that was associated with treatment.
  • Given these disappointing results, we will cease further development of the Company's drug candidates for hearing loss.

China Vaccine Market Report 2023 to 2027 - Featuring Walvax Biotechnology, Beijing Tiantan Biological Products, Sinovac Biotech and Shenzhen Kangtai Biological Products Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 31, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, Administration, Vaccination, Meningitis, Attenuated vaccine, Meningococcal disease, Rabies, MPSV4, Conjugate vaccine, Safety, Sinovac Biotech, PCV13, Expanded Program on Immunization, Infant, EPI, Sinopharm Group, Birth rate, Category, Parent, Pneumococcal polysaccharide vaccine, Forecasting, Policy, DTP, COVID-19, Category 2, R, Ageing, Pharmaceutical industry, Vaccine, Haemophilus, Immunization

As a result, China has drawn significant attention to the vaccine industry to play a representative role.

Key Points: 
  • As a result, China has drawn significant attention to the vaccine industry to play a representative role.
  • In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.
  • Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market.
  • The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Retrieved on: 
Wednesday, December 21, 2022
Ageing, Invention, RNA transfection, University of Pennsylvania, Research, Distress, HIV, Glycoprotein, Global health, Risk, BNTX, Infection, Meningitis, Herpes simplex virus, World Health Organization, HSV epigenetics, Safety, Penn, University, BioNTech, IND, Immunity, HSV, History, HSV-2, Pharmaceutical industry, Vaccine

The trial ( NCT05432583 ) will evaluate the safety, tolerability, and immunogenicity of BNT163.

Key Points: 
  • The trial ( NCT05432583 ) will evaluate the safety, tolerability, and immunogenicity of BNT163.
  • Editor’s Note: The University of Pennsylvania has licensed some intellectual property related to the BNT163 vaccine candidate to BioNTech.
  • The University of Pennsylvania receives sponsored research funding from BioNTech related to preclinical development of the BNT163 vaccine candidate.
  • As inventors of certain intellectual property related to the BNT163 vaccine candidate, some of the scientists involved in the preclinical development of the candidate along with Penn, may receive additional financial benefits under the BioNTech license in the future.

InventHelp Inventor Develops a Quick and Easy Way to Access Multiple Drill Bits (LJD-219)

Retrieved on: 
Monday, December 19, 2022
COVID-19, Measles, Tuberculosis, Multimedia, College Point, Meningitis, Infection, DEPT, Sale, Frustration, Pharmaceutical industry

THE PILL would eliminate masks from continually being lost or forgotten at home or in vehicles and the expense associated with replacing them.

Key Points: 
  • THE PILL would eliminate masks from continually being lost or forgotten at home or in vehicles and the expense associated with replacing them.
  • May also reduce the spread of various communicable diseases such as COVID-19, measles, meningitis, tuberculosis, flu, etc.
  • The original design was submitted to the Long Island, NY sales office of InventHelp.
  • 21-LJD-219, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

Retrieved on: 
Thursday, December 15, 2022
TARS, Swelling, Borrelia burgdorferi, Hypoesthesia, Inflammation, Paralysis, Salivary gland disease, Tick, Absorption, Prevalence, Security (finance), Food, FDA, Meningitis, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Science, PDUFA, Korea Disease Control and Prevention Agency, Half-life, New Drug Application, Skin, Pharmacokinetics, Paralyzed Veterans of America, Headache, CDC, Risk, Doctor of Philosophy, Myalgia, Human, Dermatology, Infection, Serum, Malaria, Vector, Nymph, Disease, Patient, Vaccine, Pharmaceutical industry, Callisto, Carpo, MD, Lyme disease

IRVINE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced positive topline results from the completed Phase 1b Callisto trial and the enrollment of the first subject in the Carpo Phase 2a trial. The Callisto and Carpo trials are designed to evaluate TP-05, a novel investigative oral therapeutic for the potential prevention of Lyme disease.

Key Points: 
  • The Callisto and Carpo trials are designed to evaluate TP-05, a novel investigative oral therapeutic for the potential prevention of Lyme disease.
  • Additionally, exploratory ex-vivo tick kill modeling utilizing serum from TP-05-treated subjects demonstrated potent, rapid killing of adult and nymph ticks.
  • Tarsus also announced the enrollment of the first patient in the Carpo trial, evaluating TP-05 for the potential prevention of Lyme disease in humans.
  • TP-05 is believed to be the only non-vaccine, drug-based, preventative therapeutic in development designed to kill ticks to potentially prevent Lyme disease transmission.

InventHelp Inventor Develops a Quick and Easy Way to Access Multiple Drill Bits (LJD-219)

Retrieved on: 
Thursday, December 8, 2022
Frustration, DEPT, College Point, Meningitis, Infection, Sale, Measles, Tuberculosis, COVID-19, Multimedia, Pharmaceutical industry

THE PILL would eliminate masks from continually being lost or forgotten at home or in vehicles and the expense associated with replacing them.

Key Points: 
  • THE PILL would eliminate masks from continually being lost or forgotten at home or in vehicles and the expense associated with replacing them.
  • May also reduce the spread of various communicable diseases such as COVID-19, measles, meningitis, tuberculosis, flu, etc.
  • The original design was submitted to the Long Island, NY sales office of InventHelp.
  • 21-LJD-219, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Travel Vaccine Global Market Report 2022: Stringent Advisories and Regulations by Health Authorities to Aid Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Other Travel, Pharmaceutical, Health, Travel, Sissel v. United States Department of Health & Human Services, COVID-19, Growth, Rotavirus, Typhoid fever, International Certificate of Vaccination or Prophylaxis, Human services, National Health Service, Health, Vaccine, Infection, Tetanus, Hepatitis B, Antibody, Hepatitis A, Fever Dream, Shingles, Tourism, Yellow fever, Travel, Cholera, Meningitis, Diphtheria, Disease, Spiritualism, Vaccination, Rubella, Mumps, Measles, Polio, Composition, Chickenpox, NHS, DPT, Rabies

The global travel vaccine market is anticipated to grow at a steady rate in the forecast period, 2023-2027.

Key Points: 
  • The global travel vaccine market is anticipated to grow at a steady rate in the forecast period, 2023-2027.
  • The market growth can be attributed to the rising incidences of flu and rapid growth in the travel and tourism sector.
  • Travel vaccines, also known as travel immunizations, are vaccine shots that protect travelers from serious illnesses.
  • Increasing regulations for safe traveling are supporting the normalization of travel vaccines among travelers, which is expected to boost the market growth.

Metagenomics Global Market Report 2022: Featuring Agilent Technologies, F. Hoffmann-La Roche, Pacific Biosciences of California & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 30, 2022
Biotechnology, Genetics, Health, COVID-19, Soil, Disease, Metagenomics, Diagnosis, Diarrhea, HIV/AIDS, Hepatitis B, Prevalence, DNA, R, Encephalitis, Genome, Ecology, Meningitis, Infection, Biofuel, Research, Water, Data analysis, Renewable energy, Vaccine, Growth

The "Metagenomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metagenomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global metagenomics market size reached US$ 452.9 Million in 2021.
  • Looking forward, the publisher expects the market to reach US$ 875 Million by 2027, exhibiting a CAGR of 11.6% during 2021-2027.
  • The publisher provides an analysis of the key trends in each sub-segment of the global metagenomics market report, along with forecasts at the global, regional and country level from 2022-2027.

Shannon Illingworth, Founder of GP Solutions, Starts "Know the Grow"

Retrieved on: 
Tuesday, November 22, 2022
Animal, Risk, American Institute of Chemical Engineers, American Institute, CBC, Food, Temperature, CDC, Mayo Clinic, Health, CORONA, Bacteria, Meningitis, Manure, Water, Herbicide, Prevalence, Centers for Disease Control and Prevention, Pesticide, Vegetable, Ticker, Food chain, Heat, Education, Clinical professor, Pharmaceutical industry, Agriculture, Food preservation, Illingworth

CORONA, Calif., Nov. 22, 2022 /PRNewswire/ -- GP Solutions, Inc (Ticker: GWPD), announced that company founder, Shannon Illingworth, has founded an organization named, "Know the Grow." The organization will focus on educating the public and increasing awareness about the dangers of pesticides, harmful chemicals, and contaminants in the U.S. food chain.

Key Points: 
  • According the Centers for Disease Control ( CDC ), food can become contaminated at many points in the food chain, from production to distribution to retail.
  • For example, fields can be irrigated with tainted water, so fruits and vegetables can be contaminated before harvest.
  • Additionally, "fresh produce can be contaminated if it is loaded into a truck that was not cleaned after transporting animals or animal products," the CDC reports.
  • Readers are cautioned to not place undue reliance on these statements, which reflect management's opinions only as of the date of this release.